Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
MENLO PARK, Calif., May 01, 2018 -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 8, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-800-239-9838 from the United States or 1-323-794-2551 internationally approximately 10 minutes before the start of the call. The passcode is 3450659.
A replay will be available through May 22, 2018 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 3450659.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® is the company’s first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
[email protected]
www.corcept.com
